Dataset Information

Proteomic and metabolomic profiling in human peripartum cardiomyopathy

ABSTRACT: Pregnancy imposes significant cardiovascular adaptations including progressive increases in plasma volume and cardiac output. For most women, this physiological adaptation resolves at the end of pregnancy, but some women develop pathological dilatation and ultimately heart failure late in pregnancy or in the postpartum period manifesting as peripartum cardiomyopathy (PPCM). Despite the mortality risk of this form of heart failure, the molecular mechanisms underlying PPCM have not been extensively examined in human hearts. We examined protein and metabolite expression in PPCM compared to familial dilated cardiomyopathy (DCM) and non-failing donors using unbiased quantitative mass spectrometry. Proteomics analysis identified uniquely downregulated proteins, such as SBSPON and TNS3, in PPCM relative to both DCM and donors. KEGG analysis of PPCM proteins identified key pathways associated with intracellular signalling cascades, protein folding and neurohormonal pathways that can directly impact the contractility of the heart. Metabolomics demonstrated uniquely expressed metabolites, such as upregulated homogentisate and deoxycholate, and downregulated lactate and alanine, along with reduced alanine, aspartate and glutamate metabolism are involved in the PPCM phenotype. Therefore, this study is the first to isolate unique molecular features underlying PPCM at the protein and metabolite level which may hold promise as future therapeutic candidate targets.

INSTRUMENT(S):

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Heart

SUBMITTER: David James

LAB HEAD: Sean Lal

PROVIDER: PXD055986 | Pride | 2025-05-07

REPOSITORIES: Pride

ACCESS DATA

Dataset's files

Source:

			Action	DRS
	20220405_Exploris_CAPFLOW_DH_BH_CM_1-059_LV_Heart.raw	Raw
	20220405_Exploris_CAPFLOW_DH_BH_CM_1-119_LV_Heart.raw	Raw
	20220405_Exploris_CAPFLOW_DH_BH_CM_1-120_LV_Heart.raw	Raw
	20220405_Exploris_CAPFLOW_DH_BH_CM_1-120_Na_Aorta.raw	Raw
	20220405_Exploris_CAPFLOW_DH_BH_CM_1-128_LV_Heart.raw	Raw

Items per page:

1 - 5 of 114

Publications

Myocardial Posttranscriptional Landscape in Peripartum Cardiomyopathy.

Li Amy A Fang Bernard B Li Mengbo M Koay Yen Chin YC Malecki Cassandra C Hunter Benjamin B Harney Dylan D Dos Remedios Cristobal G CG Larance Mark M O'Sullivan John F JF Lal Sean S

Circulation. Heart failure 20241108 12

<h4>Background</h4>Pregnancy imposes significant cardiovascular adaptations, including progressive increases in plasma volume and cardiac output. For most women, this physiological adaptation resolves at the end of pregnancy, but some women develop pathological dilatation and ultimately heart failure late in pregnancy or in the postpartum period, manifesting as peripartum cardiomyopathy (PPCM). Despite the mortality risk of this form of heart failure, the molecular mechanisms underlying PPCM hav ...[more]

PMID: 39513265

Similar Datasets

Project description:There is an emerging hypothesis that dilated cardiomyopathy (DCM) is a manifestation of end-stage heart failure (ESHF) resulting from âfinal common pathwayâ despite heterogeneous primary etiologies. We performed genome-wide expression profiling by means of high-density oligonucleotide microarrays using cardiac muscles from patients with DCM or specific cardiomyopathy as well as non-disease control hearts. Differentially expressed genes between ESHF and non-disease samples should include both genes reactive to heart failure (HF) and those responsible for ESHF. With the aid of samples with acute HF without DCM and those with DCM without HF (corrected with left ventricular assist device), we successfully distinguished ESHF genes from HF genes. Our findings implicate that transcriptional signature of cardiac muscle can be potentially applied as a diagnostic or prognostic tool for severe HF. Experiment Overall Design: The expression profiles of approximately 20,227 genes were analyzed using a microarray, Human 1A ver.2 (Agilent Technologies). A total of 30 cardiac RNA samples (21 clinical samples and 9 purchased samples) were used in the hybridizations. 200ng of total RNA was used for T7 RNA polymerase-based cRNA labeling. The microarray experiments were then carried out using competitive hybridization experiments with Cy5-labeled heart RNAs as a test RNA and with Cy3-labeled pooled heart RNA (Sample N) as a template control for normalization. The glass slides were scanned using an Agilent G2565BA microarray scanner. Scanned images were then analyzed using Feature Extraction software. The average signal intensities were corrected for median background intensity and transferred with GenBank descriptors to a Microsoft Excel data spreadsheet (Microsoft, Redmond, WA). Experiment Overall Design: Data analysis was performed using Genespring software version 6.1 (Silicon Genetics, Redwood City, CA). To avoid âfalse positiveâ signals, we excluded certain genes from the analysis for which the average reference signal level constraints were under 70. After intensity dependent normalization (Lowess), the expression levels relative to the control were calculated as a ratio, and the expression profiles were then compared between each disease or normal sample. Statistical analysis was done using non-parametric tests. To order the samples according to the correlation coefficient, we applied âFind Similar Samplesâ algorithm using Spearman Correlation.